The success of Forest Laboratories has resulted from its ability to identify drug candidates with the potential to fulfill unmet medical needs or provide benefits over currently available medications.

Forest Laboratories is a U.S.-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a difference in people’s lives. Our company has well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, and is always exploring new product opportunities across therapeutic categories to address a broad spectrum of health conditions.

Forest Laboratories partners with pharmaceutical and biotech companies to develop all of our marketed products, licensing or acquiring promising new products from innovative companies worldwide at virtually every stage of development. Forest conducts rigorous scientific investigation of its licensed drugs, and executes focused marketing and sales initiatives to firmly establish its products in the marketplace.

Financial Highlights Fiscal Year Ended March 31

(In thousands, except per share data)	2011	2010
Net Revenues	$4,419,700	$4,192,862
Income (before income taxes)	1,337,736	950,686
Income Taxes	290,966	268,303
Net Income	1,046,770	682,383
Earnings per common and common equivalent shares - diluted	$3.59	$2.25
Weighted Average of common and common equivalent shares outstanding - diluted	291,175	303,781

All amounts give effect to the two-for-one stock split effected as a 100% stock dividend in Dec. 2002.

Transfer Agent

Mellon Investor Services, LLC 85 Challenger Road Ridgefield Park, NJ 07660 Phone: 800-313-9450